This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Exisulind
Accession Number
DB06246
Type
Small Molecule
Groups
Investigational
Description
Not Available
Structure
Thumb
Synonyms
  • FGN 1
  • sulindac sulfone
International/Other Brands
Aptosyn (OSI Pharmaceuticals Inc.) / Prevetac (Cell Pathways Inc.)
Categories
UNII
K619IIG2R9
CAS number
59973-80-7
Weight
Average: 372.41
Monoisotopic: 372.083158364
Chemical Formula
C20H17FO4S
InChI Key
MVGSNCBCUWPVDA-MFOYZWKCSA-N
InChI
InChI=1S/C20H17FO4S/c1-12-17(9-13-3-6-15(7-4-13)26(2,24)25)16-8-5-14(21)10-19(16)18(12)11-20(22)23/h3-10H,11H2,1-2H3,(H,22,23)/b17-9-
IUPAC Name
2-[(1Z)-5-fluoro-1-[(4-methanesulfonylphenyl)methylidene]-2-methyl-1H-inden-3-yl]acetic acid
SMILES
CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(C=C1)S(C)(=O)=O

Pharmacology

Indication

Investigated for use/treatment in adenomatous polyposis coli, lung cancer, prostate cancer, colon polyps, Barrett's esophagus disease, and pediatric indications.

Pharmacodynamics
Not Available
Mechanism of action

Exisulind is a sulindac derivative of a class of compounds called selective apoptotic anti-neoplastic drugs (SAANDs), which inhibit the enzyme cyclic guanosine monophosphodiesterase (cGMP - PDE). Exisulind is specific for apoptotic effects in precancerous and cancerous colorectal cells due to their overexpression of cGMP. Sustained elevation of cGMP and protein kinase G (PKG) activation may be also implicated in the induction of apoptosis by Exisulind.

TargetActionsOrganism
UcAMP-specific 3',5'-cyclic phosphodiesterase 4DNot AvailableHuman
UcAMP-specific 3',5'-cyclic phosphodiesterase 4CNot AvailableHuman
UcGMP-specific 3',5'-cyclic phosphodiesteraseNot AvailableHuman
UcGMP-dependent 3',5'-cyclic phosphodiesteraseNot AvailableHuman
UGlutathione S-transferase P
inhibitor
Human
UAldose reductase
inhibitor
Human
UAldo-keto reductase family 1 member B10
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when Exisulind is combined with (4R)-limonene.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Exisulind is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Exisulind is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Exisulind is combined with 5-androstenedione.Experimental, Illicit
AbciximabExisulind may increase the anticoagulant activities of Abciximab.Approved
AcebutololExisulind may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Exisulind is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Exisulind is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolExisulind may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcetaminophenThe risk or severity of adverse effects can be increased when Exisulind is combined with Acetaminophen.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Exisulind.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Exisulind.Experimental
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Exisulind is combined with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Exisulind.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Exisulind is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Exisulind is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Exisulind is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Exisulind is combined with Alendronic acid.Approved
AliskirenExisulind may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Exisulind is combined with Alminoprofen.Experimental
AlprenololExisulind may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Exisulind.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Exisulind is combined with Amcinonide.Approved
AmikacinExisulind may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Investigational, Vet Approved
AmilorideExisulind may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Exisulind is combined with Aminosalicylic Acid.Approved
AmiodaroneExisulind may decrease the antihypertensive activities of Amiodarone.Approved, Investigational
AncestimThe risk or severity of cytotoxicity can be increased when Ancestim is combined with Exisulind.Approved, Investigational, Withdrawn
AncrodExisulind may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Exisulind.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Exisulind is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Exisulind is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Exisulind is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Exisulind is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Exisulind is combined with Antipyrine.Approved, Investigational
Antithrombin III humanExisulind may increase the anticoagulant activities of Antithrombin III human.Approved
AntrafenineThe risk or severity of adverse effects can be increased when Exisulind is combined with Antrafenine.Approved
ApixabanExisulind may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Exisulind is combined with Apocynin.Investigational
ApramycinExisulind may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Exisulind.Approved, Investigational
ArbekacinExisulind may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinExisulind may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanExisulind may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololExisulind may decrease the antihypertensive activities of Arotinolol.Investigational
AsenapineExisulind may decrease the antihypertensive activities of Asenapine.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Exisulind is combined with Atamestane.Investigational
AtenololExisulind may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Exisulind is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Exisulind.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Exisulind is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Exisulind.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Exisulind.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Exisulind is combined with Balsalazide.Approved, Investigational
BecaplerminExisulind may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Exisulind is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololExisulind may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinExisulind may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Exisulind is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Exisulind is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Exisulind.Approved
BenorilateThe risk or severity of adverse effects can be increased when Exisulind is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Exisulind.Withdrawn
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Exisulind.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Exisulind is combined with Benzydamine.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Exisulind.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Exisulind is combined with Betamethasone.Approved, Vet Approved
BetaxololExisulind may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Exisulind.Approved, Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Exisulind.Approved, Investigational
BevantololExisulind may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Exisulind is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Exisulind.Approved, Investigational
BisoprololExisulind may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinExisulind may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololExisulind may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Exisulind is combined with Bromfenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Exisulind is combined with Bucillamine.Investigational
BucindololExisulind may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Exisulind is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Exisulind is combined with Bufexamac.Approved, Experimental
BufuralolExisulind may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Exisulind is combined with Bumadizone.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Exisulind.Approved
BupranololExisulind may decrease the antihypertensive activities of Bupranolol.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Exisulind.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Exisulind.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Exisulind.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Exisulind is combined with Candoxatril.Experimental
CapsaicinThe risk or severity of adverse effects can be increased when Exisulind is combined with Capsaicin.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Exisulind is combined with Captopril.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Exisulind is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Exisulind.Approved
CarprofenThe risk or severity of adverse effects can be increased when Exisulind is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololExisulind may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolExisulind may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Exisulind.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Exisulind is combined with Celecoxib.Approved, Investigational
CeliprololExisulind may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinExisulind may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Exisulind.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Exisulind.Approved, Vet Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Exisulind is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Exisulind.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Exisulind resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Exisulind is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Exisulind is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Exisulind is combined with Cilazapril.Approved
CimicoxibThe risk or severity of adverse effects can be increased when Exisulind is combined with Cimicoxib.Investigational
CinoxacinExisulind may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinExisulind may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CisplatinThe risk or severity of adverse effects can be increased when Exisulind is combined with Cisplatin.Approved
Citric AcidExisulind may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Exisulind is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Exisulind is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Exisulind is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Exisulind is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Exisulind is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Exisulind is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Exisulind.Vet Approved
CloranololExisulind may decrease the antihypertensive activities of Cloranolol.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Exisulind resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Exisulind resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Exisulind is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Exisulind is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Exisulind is combined with Cortisone acetate.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Exisulind is combined with Curcumin.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Exisulind.Experimental
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Exisulind.Approved, Investigational
CyclosporineExisulind may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Exisulind.Experimental
Dabigatran etexilateExisulind may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinExisulind may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidExisulind may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanExisulind may increase the anticoagulant activities of Darexaban.Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Exisulind is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Exisulind is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Exisulind is combined with Delapril.Experimental
DesipramineExisulind may decrease the antihypertensive activities of Desipramine.Approved, Investigational
DesirudinExisulind may increase the anticoagulant activities of Desirudin.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Exisulind.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Exisulind is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Exisulind is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Exisulind is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Exisulind is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Exisulind is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Exisulind is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Exisulind is combined with Dexamethasone isonicotinate.Vet Approved
DexibuprofenThe risk or severity of adverse effects can be increased when Exisulind is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Exisulind.Approved, Investigational
DextranExisulind may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DibekacinExisulind may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Exisulind is combined with Dibotermin alfa.Approved, Investigational
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Exisulind.Approved, Vet Approved
DicoumarolExisulind may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Exisulind is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Exisulind is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Exisulind is combined with Diflunisal.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Exisulind is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Exisulind is combined with Difluprednate.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Exisulind.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Exisulind.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Exisulind.Approved
DihydrostreptomycinExisulind may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Exisulind.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Exisulind.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Exisulind.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Exisulind.Approved, Investigational
DrospirenoneExisulind may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Exisulind is combined with Droxicam.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Exisulind is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Exisulind is combined with E-6201.Investigational
Edetic AcidExisulind may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanExisulind may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Exisulind is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Exisulind is combined with Enalaprilat.Approved
EnoxacinExisulind may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinExisulind may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Exisulind.Experimental
EpanololExisulind may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Exisulind is combined with Epirizole.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Exisulind.Experimental
EplerenoneExisulind may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Exisulind.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Exisulind.Approved
EquileninThe risk or severity of adverse effects can be increased when Exisulind is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Exisulind is combined with Equilin.Approved
EsatenololExisulind may decrease the antihypertensive activities of Esatenolol.Experimental
EsmololExisulind may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Exisulind is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Exisulind is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Exisulind.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Exisulind is combined with Etanercept.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Exisulind is combined with Ethenzamide.Experimental
Ethyl biscoumacetateExisulind may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Exisulind is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Exisulind is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Exisulind is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Exisulind is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Exisulind is combined with Evening primrose oil.Investigational, Nutraceutical
FelbinacThe risk or severity of adverse effects can be increased when Exisulind is combined with Felbinac.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Exisulind is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Exisulind is combined with Fenoprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Exisulind.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Exisulind is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Exisulind is combined with Feprazone.Experimental
Ferulic acidExisulind may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Exisulind.Approved, Investigational
Fish oilThe risk or severity of adverse effects can be increased when Exisulind is combined with Fish oil.Approved, Nutraceutical
FleroxacinExisulind may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Exisulind.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Exisulind is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Exisulind is combined with Fludrocortisone.Approved, Investigational
FluindioneExisulind may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineExisulind may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Exisulind is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Exisulind is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Exisulind is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Exisulind is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Exisulind is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Exisulind is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Exisulind is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Exisulind is combined with Fluorometholone.Approved, Investigational
FluprednideneThe risk or severity of adverse effects can be increased when Exisulind is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Exisulind is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Exisulind.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Exisulind is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Exisulind is combined with Flurbiprofen.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Exisulind is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Exisulind is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Exisulind is combined with Fluticasone propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Exisulind.Approved, Nutraceutical, Vet Approved
FondaparinuxExisulind may increase the anticoagulant activities of Fondaparinux.Approved, Investigational
Fondaparinux sodiumExisulind may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Exisulind.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Exisulind is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Exisulind is combined with Fosinopril.Approved
FramycetinExisulind may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Exisulind.Approved, Vet Approved
GabexateExisulind may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinExisulind may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinExisulind may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Exisulind.Approved, Withdrawn
GemifloxacinExisulind may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinExisulind may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinExisulind may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AExisulind may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GinsengThe risk or severity of adverse effects can be increased when Exisulind is combined with Ginseng.Approved, Investigational, Nutraceutical
GitoformateGitoformate may decrease the cardiotoxic activities of Exisulind.Experimental
GrepafloxacinExisulind may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Exisulind is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Exisulind is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Exisulind is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Exisulind is combined with HE3286.Investigational
HeparinExisulind may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Exisulind is combined with Higenamine.Investigational
HydralazineExisulind may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Exisulind.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Exisulind is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Exisulind.Approved, Investigational
Hygromycin BExisulind may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Exisulind is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Exisulind is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Exisulind is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Exisulind.Approved, Investigational
IcosapentThe risk or severity of adverse effects can be increased when Exisulind is combined with Icosapent.Approved, Nutraceutical
IdraparinuxExisulind may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Exisulind.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Exisulind is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Exisulind is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Exisulind.Approved
IndenololExisulind may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Exisulind is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Exisulind is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Exisulind is combined with Indoprofen.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Exisulind.Approved, Investigational
IsepamicinExisulind may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Exisulind is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Exisulind is combined with Istaroxime.Investigational
KanamycinExisulind may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Exisulind is combined with Kebuzone.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Exisulind is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Exisulind.Approved
LabetalolExisulind may decrease the antihypertensive activities of Labetalol.Approved
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Exisulind.Experimental
LandiololExisulind may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Exisulind.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Exisulind.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Exisulind.Approved, Investigational
LepirudinExisulind may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanExisulind may increase the anticoagulant activities of Letaxaban.Investigational
LevobetaxololExisulind may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
LevobunololExisulind may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinExisulind may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Exisulind.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Exisulind is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Exisulind is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Exisulind.Approved
LomefloxacinExisulind may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Exisulind is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Exisulind is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Exisulind.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Exisulind is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Exisulind is combined with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Exisulind.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Exisulind is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Exisulind.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Exisulind is combined with Magnesium salicylate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Exisulind.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Exisulind is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Exisulind is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Exisulind is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Exisulind is combined with Mefenamic acid.Approved
MelagatranExisulind may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Exisulind is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Exisulind is combined with Meloxicam.Approved, Vet Approved
MepindololExisulind may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Exisulind is combined with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Exisulind.Approved, Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Exisulind.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Exisulind.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Exisulind is combined with Methylprednisolone.Approved, Vet Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Exisulind.Experimental
MetipranololExisulind may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Exisulind.Approved
MetoprololExisulind may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MicronomicinExisulind may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Exisulind.Approved, Experimental
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Exisulind.Approved
MizoribineThe risk or severity of adverse effects can be increased when Exisulind is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Exisulind is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Exisulind is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Exisulind is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Exisulind.Approved
MoxifloxacinExisulind may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Exisulind.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Exisulind.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Exisulind is combined with Nabumetone.Approved
NadololExisulind may decrease the antihypertensive activities of Nadolol.Approved
NadroparinExisulind may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatExisulind may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Exisulind.Approved
Nalidixic AcidExisulind may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Exisulind is combined with Naproxen.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Exisulind is combined with NCX 1022.Investigational
NeamineExisulind may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololExisulind may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinExisulind may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinExisulind may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Exisulind is combined with Nepafenac.Approved, Investigational
NetilmicinExisulind may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Exisulind is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Exisulind is combined with Niflumic Acid.Approved
NimesulideThe risk or severity of adverse effects can be increased when Exisulind is combined with Nimesulide.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Exisulind is combined with Nitroaspirin.Investigational
NorfloxacinExisulind may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinExisulind may increase the neuroexcitatory activities of Ofloxacin.Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Exisulind.Experimental, Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Exisulind is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Exisulind.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Exisulind.Approved
OlsalazineExisulind may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Exisulind is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Exisulind is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Exisulind is combined with Orgotein.Vet Approved
OtamixabanExisulind may increase the anticoagulant activities of Otamixaban.Investigational
OuabainOuabain may decrease the cardiotoxic activities of Exisulind.Approved
OxaprozinThe risk or severity of adverse effects can be increased when Exisulind is combined with Oxaprozin.Approved
Oxolinic acidExisulind may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololExisulind may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Exisulind.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Exisulind.Approved, Vet Approved
PalmidrolThe risk or severity of adverse effects can be increased when Exisulind is combined with Palmidrol.Experimental, Nutraceutical
PamidronateThe risk or severity of adverse effects can be increased when Exisulind is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Exisulind is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Exisulind is combined with Parecoxib.Approved
ParomomycinExisulind may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Exisulind is combined with Parthenolide.Approved, Investigational
PazufloxacinExisulind may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinExisulind may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololExisulind may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateExisulind may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateExisulind may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Exisulind is combined with Perindopril.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Exisulind.Experimental
PhenindioneExisulind may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonExisulind may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Exisulind is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Exisulind.Approved, Investigational
PindololExisulind may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acidExisulind may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Exisulind.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Exisulind.Approved, Investigational
Piromidic acidExisulind may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Exisulind is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Exisulind is combined with Pirprofen.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Exisulind is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorExisulind may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinExisulind may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Exisulind.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Exisulind is combined with Pomalidomide.Approved
Potassium CitrateExisulind may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PractololExisulind may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Exisulind.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Exisulind is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Exisulind is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Exisulind is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Exisulind is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Exisulind is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Exisulind is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Exisulind is combined with Pregnenolone.Approved, Experimental, Investigational
ProbenecidThe serum concentration of Exisulind can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Exisulind is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Exisulind is combined with Propacetamol.Approved, Investigational
PropafenoneExisulind may decrease the antihypertensive activities of Propafenone.Approved
PropranololExisulind may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Exisulind is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Exisulind is combined with Proquazone.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Exisulind.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Exisulind.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Exisulind.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Exisulind.Vet Approved
Protein CExisulind may increase the anticoagulant activities of Protein C.Approved
Protein S humanExisulind may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeExisulind may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinExisulind may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Exisulind.Investigational
PuromycinExisulind may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Exisulind is combined with Quinapril.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Exisulind.Approved
RamiprilThe risk or severity of adverse effects can be increased when Exisulind is combined with Ramipril.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Exisulind is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Exisulind is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinExisulind may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinExisulind may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Exisulind is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Exisulind is combined with Risedronate.Approved, Investigational
RivaroxabanExisulind may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Exisulind is combined with Rofecoxib.Approved, Investigational, Withdrawn
RosoxacinExisulind may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinExisulind may increase the neuroexcitatory activities of Rufloxacin.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Exisulind.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Exisulind is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Exisulind is combined with Salicylic acid.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Exisulind is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Exisulind.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Exisulind.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Exisulind.Approved, Investigational
SeliciclibThe risk or severity of adverse effects can be increased when Exisulind is combined with Seliciclib.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Exisulind is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Exisulind is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Exisulind is combined with Serrapeptase.Investigational
SisomicinExisulind may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinExisulind may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium CitrateExisulind may increase the anticoagulant activities of Sodium Citrate.Approved, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Exisulind.Approved
SotalolExisulind may decrease the antihypertensive activities of Sotalol.Approved
SparfloxacinExisulind may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpiraprilThe risk or severity of adverse effects can be increased when Exisulind is combined with Spirapril.Approved
SpironolactoneExisulind may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Exisulind.Investigational
StreptomycinExisulind may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Exisulind is combined with Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Exisulind is combined with Sulindac.Approved, Investigational
SulodexideExisulind may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Exisulind.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Exisulind is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Exisulind is combined with Suxibuzone.Experimental
TacrolimusExisulind may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Exisulind.Approved
TalinololExisulind may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Exisulind.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Exisulind.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Exisulind.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Exisulind is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Exisulind is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Exisulind.Approved, Investigational
TemafloxacinExisulind may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Exisulind is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Exisulind is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Exisulind is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Exisulind is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Exisulind is combined with Tepoxalin.Vet Approved
TerbutalineExisulind may decrease the antihypertensive activities of Terbutaline.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Exisulind is combined with Teriflunomide.Approved
TertatololExisulind may decrease the antihypertensive activities of Tertatolol.Experimental
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Exisulind is combined with Tiaprofenic acid.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Exisulind is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololExisulind may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Exisulind is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Exisulind is combined with Tixocortol.Approved, Withdrawn
TobramycinExisulind may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Exisulind is combined with Tolfenamic Acid.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Exisulind is combined with Tolmetin.Approved
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Exisulind.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Exisulind is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Exisulind is combined with Tranilast.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Exisulind.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Exisulind.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Exisulind.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Exisulind is combined with Triamcinolone.Approved, Vet Approved
TriamtereneExisulind may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Exisulind is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Exisulind.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Exisulind is combined with Triptolide.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Exisulind is combined with Trolamine salicylate.Approved
TrovafloxacinExisulind may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinExisulind may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Exisulind is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Exisulind.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Exisulind is combined with Valdecoxib.Approved, Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Exisulind.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Exisulind.Approved
WarfarinExisulind may increase the anticoagulant activities of Warfarin.Approved
XimelagatranExisulind may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Exisulind is combined with Zaltoprofen.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Exisulind.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Exisulind is combined with Zofenopril.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Exisulind is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Exisulind.Withdrawn
Food Interactions
Not Available

References

General References
  1. Authors unspecified: Exisulind: Aptosyn, FGN 1, Prevatac, sulindac sulfone. Drugs R D. 2004;5(4):220-6. [PubMed:15230629]
  2. Piazza GA, Thompson WJ, Pamukcu R, Alila HW, Whitehead CM, Liu L, Fetter JR, Gresh WE Jr, Klein-Szanto AJ, Farnell DR, Eto I, Grubbs CJ: Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis. Cancer Res. 2001 May 15;61(10):3961-8. [PubMed:11358813]
  3. Thompson WJ, Piazza GA, Li H, Liu L, Fetter J, Zhu B, Sperl G, Ahnen D, Pamukcu R: Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res. 2000 Jul 1;60(13):3338-42. [PubMed:10910034]
External Links
ChemSpider
4582441
ChEBI
64212
ChEMBL
CHEMBL488025
HET
SLO
Wikipedia
Exisulind
PDB Entries
3rx2

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1, 2CompletedTreatmentNeoplasm Metastases / Neoplasms, Breast1
2CompletedPreventionProstatic Neoplasms1
2CompletedTreatmentLung Cancers2
2CompletedTreatmentProstate Cancer3
2CompletedTreatmentProstatic Neoplasms1
2, 3WithdrawnPreventionColorectal Cancers / Small Intestine Cancer1
3CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00155 mg/mLALOGPS
logP2.94ALOGPS
logP3.03ChemAxon
logS-5.4ALOGPS
pKa (Strongest Acidic)3.94ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area71.44 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity99.2 m3·mol-1ChemAxon
Polarizability38.03 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Ubiquitin protein ligase binding
Specific Function
Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes.
Gene Name
PDE4D
Uniprot ID
Q08499
Uniprot Name
cAMP-specific 3',5'-cyclic phosphodiesterase 4D
Molecular Weight
91114.1 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Metal ion binding
Specific Function
Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes.
Gene Name
PDE4C
Uniprot ID
Q08493
Uniprot Name
cAMP-specific 3',5'-cyclic phosphodiesterase 4C
Molecular Weight
79900.795 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Metal ion binding
Specific Function
Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. This phosphodiesterase catalyzes the specific hydrolysis of cGMP to 5'-GMP (PubMed:9714779, ...
Gene Name
PDE5A
Uniprot ID
O76074
Uniprot Name
cGMP-specific 3',5'-cyclic phosphodiesterase
Molecular Weight
99984.14 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Tpr domain binding
Specific Function
Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes.Isoform PDE2A2: Regulates Mit...
Gene Name
PDE2A
Uniprot ID
O00408
Uniprot Name
cGMP-dependent 3',5'-cyclic phosphodiesterase
Molecular Weight
105715.85 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
S-nitrosoglutathione binding
Specific Function
Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. Regulates negatively CDK5 activity via p25/p35 translocation to prevent neurodegeneration.
Gene Name
GSTP1
Uniprot ID
P09211
Uniprot Name
Glutathione S-transferase P
Molecular Weight
23355.625 Da
References
  1. Nobuoka A, Takayama T, Miyanishi K, Sato T, Takanashi K, Hayashi T, Kukitsu T, Sato Y, Takahashi M, Okamoto T, Matsunaga T, Kato J, Oda M, Azuma T, Niitsu Y: Glutathione-S-transferase P1-1 protects aberrant crypt foci from apoptosis induced by deoxycholic acid. Gastroenterology. 2004 Aug;127(2):428-43. [PubMed:15300575]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Glyceraldehyde oxidoreductase activity
Specific Function
Catalyzes the NADPH-dependent reduction of a wide variety of carbonyl-containing compounds to their corresponding alcohols with a broad range of catalytic efficiencies.
Gene Name
AKR1B1
Uniprot ID
P15121
Uniprot Name
Aldose reductase
Molecular Weight
35853.125 Da
References
  1. Zheng X, Zhang L, Zhai J, Chen Y, Luo H, Hu X: The molecular basis for inhibition of sulindac and its metabolites towards human aldose reductase. FEBS Lett. 2012 Jan 2;586(1):55-9. doi: 10.1016/j.febslet.2011.11.023. Epub 2011 Dec 8. [PubMed:22155003]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Retinal dehydrogenase activity
Specific Function
Acts as all-trans-retinaldehyde reductase. Can efficiently reduce aliphatic and aromatic aldehydes, and is less active on hexoses (in vitro). May be responsible for detoxification of reactive aldeh...
Gene Name
AKR1B10
Uniprot ID
O60218
Uniprot Name
Aldo-keto reductase family 1 member B10
Molecular Weight
36019.295 Da
References
  1. Cousido-Siah A, Ruiz FX, Crespo I, Porte S, Mitschler A, Pares X, Podjarny A, Farres J: Structural analysis of sulindac as an inhibitor of aldose reductase and AKR1B10. Chem Biol Interact. 2015 Jun 5;234:290-6. doi: 10.1016/j.cbi.2014.12.018. Epub 2014 Dec 20. [PubMed:25532697]

Drug created on March 19, 2008 10:19 / Updated on June 02, 2018 07:42